发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type. 原发性皮肤弥漫性大B细胞淋巴瘤-腿型的发病机制及治疗现状。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-20 DOI: 10.1080/10428194.2025.2506503
Ewa Robak, Marcin Braun, Tadeusz Robak
{"title":"A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type.","authors":"Ewa Robak, Marcin Braun, Tadeusz Robak","doi":"10.1080/10428194.2025.2506503","DOIUrl":"10.1080/10428194.2025.2506503","url":null,"abstract":"<p><p>Primary cutaneous diffuse large B cell lymphoma, leg type (PCDLBCL-LT) is an aggressive B cell extranodal variant of lymphoma present in the skin, typically without evidence of extra cutaneous spread at the time of diagnosis. PCDLBCL-LT accounts for 20% of all primary cutaneous B cell lymphomas (CBCL) and 5% of all primary cutaneous lymphomas (PCL). It is more common in the elderly (median age 75 years). The disease commonly manifests as rapidly-growing red to bluish often ulcerating, nodular tumors, plaques or violaceous nodules on one or both lower extremities. Only 10% to 15% of lesions develop in other areas. A prognosis of PCDLBCL-LT is poor, with a 5-year survival rate of 40 to 50%. The first-line treatment of PCDLBCL-LT includes immunochemotherapy, most commonly R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone). In the case of a solitary lesion, excision or radiotherapy should be considered. Many patients demonstrate cutaneous relapses (70%) or systemic dissemination (50%). Recent studies have reported the use of Bruton's tyrosine-kinase (BTK) inhibitors, BCL2 inhibitors, immunomodulatory drugs and immune check-point inhibitors in treating relapsed or refractory patients. The study summarizes the current view of the pathogenesis, diagnosis and treatment of PCDLBCL-LT, including genetic abnormalities and novel targeted drugs.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1603-1614"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. 口服地西他滨-cedazuridine联合venetoclax治疗母细胞浆细胞样树突状细胞肿瘤病例系列。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-04-30 DOI: 10.1080/10428194.2025.2498046
Hannah Goulart, Guillermo Garcia-Manero, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Muzaffar Qazilbash, Caitlin Rausch, Gabriela Llaurador Caraballo, Sherry Pierce, Naveen Pemmaraju
{"title":"A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm.","authors":"Hannah Goulart, Guillermo Garcia-Manero, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Muzaffar Qazilbash, Caitlin Rausch, Gabriela Llaurador Caraballo, Sherry Pierce, Naveen Pemmaraju","doi":"10.1080/10428194.2025.2498046","DOIUrl":"10.1080/10428194.2025.2498046","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1727-1730"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in T-cell lymphomas and risk factors for CNS involvement. t细胞淋巴瘤及其累及中枢神经系统的危险因素研究进展。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-07-01 DOI: 10.1080/10428194.2025.2510524
Omar Elghawy, Nishwant Swami, Zachary A Hing, Stefan K Barta
{"title":"Advances in T-cell lymphomas and risk factors for CNS involvement.","authors":"Omar Elghawy, Nishwant Swami, Zachary A Hing, Stefan K Barta","doi":"10.1080/10428194.2025.2510524","DOIUrl":"10.1080/10428194.2025.2510524","url":null,"abstract":"<p><p>T-cell lymphomas (TCLs) are rare heterogenous hematologic neoplasms that exhibit poor response to traditional cytotoxic chemotherapy and have no universally accepted gold standard of treatment. Central nervous system (CNS) involvement is rare and generally associated with poor prognosis and increased morbidity. The identification of clinicopathologic risk factors for CNS relapse has been evaluated in recent years, and the development of predictive multivariable models remains an active area of study. This review summarizes the epidemiology, risk factors and treatment of both primary and relapsed TCL with and without CNS involvement and describes multiple therapeutic strategies that have been explored for the treatment of TCLs including epigenetic modulation, chimeric antigen receptor T-cell therapy, and immunotherapy.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1583-1602"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant. “完美匹配”：血液学家如何与考虑同种异体干细胞移植的黑人和白人患者讨论供体选择和风险。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1080/10428194.2025.2500625
Thorunn H Thordardottir, Rachel A Rodenbach, Markus Brauer, Aric C Hall, Earlise Ward, Cardinale B Smith, Toby C Campbell
{"title":"'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant.","authors":"Thorunn H Thordardottir, Rachel A Rodenbach, Markus Brauer, Aric C Hall, Earlise Ward, Cardinale B Smith, Toby C Campbell","doi":"10.1080/10428194.2025.2500625","DOIUrl":"10.1080/10428194.2025.2500625","url":null,"abstract":"<p><p>Patients of racial minorities have lower chance of securing a suitable donor, essential part of successful allogeneic stem cell transplant. In this simulated interview study, we sought to examine how hematologists discuss donor options and risks with patients with high-risk myeloid neoplasm considering transplant. Thirty-seven US hematologists participated (65% male; 65% white, 24% Asian, none Black), randomly assigned to meet with a Black or white patient actor. The hematologists emphasized the benefits of a full match with the white patient and high chance of securing a donor. Conversely, with the Black patient, they tended not to ask about ancestry, discuss the donor registry, race implications or challenges with donor search. Knowing the patient had children, many recommended haploidentical transplant. The unique circumstances of transplant argue for a focused communication including discussing race. While conversations should be tailored to each patient, limiting essential information on donor options may contribute to disparities.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1636-1645"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The paradox of the spleen: is it a nodal or extranodal site of lymphoma? 脾脏的悖论：它是淋巴结淋巴瘤还是结外淋巴瘤？
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-04-22 DOI: 10.1080/10428194.2025.2495112
Robert Puckrin
{"title":"The paradox of the spleen: is it a nodal or extranodal site of lymphoma?","authors":"Robert Puckrin","doi":"10.1080/10428194.2025.2495112","DOIUrl":"10.1080/10428194.2025.2495112","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1756-1758"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera. 验证aaa模型（年龄，绝对中性粒细胞计数，绝对淋巴细胞计数）用于预测1000例真性红细胞增多症患者的生存和血栓形成。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.1080/10428194.2025.2503458
Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak
{"title":"Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera.","authors":"Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak","doi":"10.1080/10428194.2025.2503458","DOIUrl":"10.1080/10428194.2025.2503458","url":null,"abstract":"<p><p>Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x10<sup>9</sup>/L) absolute neutrophil and low(<1.7 × 10<sup>9</sup>/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1625-1635"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of maintenance therapy and its cessation in patients with multiple myeloma. 维持治疗和停止治疗在多发性骨髓瘤患者中的作用。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-08-28 DOI: 10.1080/10428194.2025.2551785
Abigail P Sneider, Benjamin A Derman
{"title":"The role of maintenance therapy and its cessation in patients with multiple myeloma.","authors":"Abigail P Sneider, Benjamin A Derman","doi":"10.1080/10428194.2025.2551785","DOIUrl":"https://doi.org/10.1080/10428194.2025.2551785","url":null,"abstract":"<p><p>Lenalidomide maintenance therapy remains a cornerstone of post-induction treatment in multiple myeloma (MM), supported by various landmark trials demonstrating improved outcomes with lenalidomide maintenance over observation or placebo following autologous stem cell transplant (ASCT). Despite advancements in the MM treatment landscape, including the integration of quadruplet induction therapies and measurable residual disease (MRD) assessment to define deep responses, most maintenance strategies continue to focus on maintenance intensification rather than de-escalation. With an increasing number of patients achieving sustained deep responses, the optimal application and duration of maintenance therapy deserve reevaluation. This manuscript explores the rationale behind maintenance therapy in MM, examining the long-term benefits and adverse effects of ongoing treatment, state-of-the-art approaches to maintenance, and MRD-driven approaches to potentially de-escalate, discontinue, or eschew maintenance altogether.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives. 复发难治性外周t细胞淋巴瘤；治疗、挑战和未来展望。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-08-28 DOI: 10.1080/10428194.2025.2545927
Frederik O Meeuwes, Yasmina I M Serroukh, Marjolein W M van der Poel, Wouter J Plattel, Marcel Nijland
{"title":"Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives.","authors":"Frederik O Meeuwes, Yasmina I M Serroukh, Marjolein W M van der Poel, Wouter J Plattel, Marcel Nijland","doi":"10.1080/10428194.2025.2545927","DOIUrl":"https://doi.org/10.1080/10428194.2025.2545927","url":null,"abstract":"<p><p>Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of 15 different neoplasms in adults. In Europe and North America, PTCL not otherwise specified (PTCL NOS), nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI), and anaplastic large cell lymphoma (ALCL) either anaplastic lymphoma kinase (ALK) positive (+) or negative (-) are the most prevalent PTCLs. Relapsed or refractory disease (R/R) is common in PTCL and its management is challenging. Despite response rates and prognoses being disease specific, the outcome of R/R PTCL is dismal except for R/R ALK+ ALCL. Populations in R/R PTCL studies have mostly been heterogeneous and encompassing several entities. While there are many treatment options for R/R PTCL such as salvage chemotherapy, autologous or allogeneic stem cell transplant, epigenetic drugs, monoclonal antibodies, and small molecules, responses are limited and few are curative. Here we review the management of R/R PTCL, focusing on ALCL, nTFHL, and PTCL NOS.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-16"},"PeriodicalIF":2.2,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute leukemia of ambiguous lineage with KMT2A-alterations in adults. 成人kmt2a突变的不明谱系急性白血病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-08-25 DOI: 10.1080/10428194.2025.2547988
Steven Tessier, Patricia T Greipp, Dragan Jevremovic, Hassan B Alkhateeb, Aref Al-Kali, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Antoine N Saliba, Naseema Gangat, James M Foran, Cecilia Y Arana Yi, Ayalew Tefferi, Kebede H Begna
{"title":"Acute leukemia of ambiguous lineage with <i>KMT2A</i>-alterations in adults.","authors":"Steven Tessier, Patricia T Greipp, Dragan Jevremovic, Hassan B Alkhateeb, Aref Al-Kali, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Antoine N Saliba, Naseema Gangat, James M Foran, Cecilia Y Arana Yi, Ayalew Tefferi, Kebede H Begna","doi":"10.1080/10428194.2025.2547988","DOIUrl":"https://doi.org/10.1080/10428194.2025.2547988","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings. 影响低风险骨髓增生异常综合征治疗决策的因素。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-08-25 DOI: 10.1080/10428194.2025.2547998
Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, Justin M Watts, Terrence Bradley, Justin Taylor, David A Sallman, Zhuoer Xie, Eric Padron, Emily Zyborowicz, Chelsie Anderson Chadha, Jeffrey Carter, Cherilyn Heggen, Shelby Sullivan, Lindsay Gurska, Rami S Komrokji
{"title":"Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.","authors":"Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, Justin M Watts, Terrence Bradley, Justin Taylor, David A Sallman, Zhuoer Xie, Eric Padron, Emily Zyborowicz, Chelsie Anderson Chadha, Jeffrey Carter, Cherilyn Heggen, Shelby Sullivan, Lindsay Gurska, Rami S Komrokji","doi":"10.1080/10428194.2025.2547998","DOIUrl":"https://doi.org/10.1080/10428194.2025.2547998","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信